Huiwen Jiang

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

BMSCs-AML cell interaction drives FLT3 inhibitor resistance through the NR2F2/COX-2/PGE2 Axis.

BMSCs-AML cell interaction drives FLT3 inhibitor resistance through the NR2F2/COX-2/PGE2 Axis.

Journal: Cellular signalling

Published: May 14, 2026

Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.

Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.

Journal: Thrombosis research

Published: May 13, 2025

Integrin αvβ8-mediated TGF-β1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal.

Integrin αvβ8-mediated TGF-β1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal.

Journal: Blood

Published: April 29, 2025

Integrin αvβ8-mediated TGF-β1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.

Integrin αvβ8-mediated TGF-β1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.

Journal: Blood

Published: April 29, 2025

Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.

Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.

Journal: Annals of hematology

Published: March 11, 2025

Effect of interferon induced transmembrane protein 1 ( IFITM1 ) upregulation to cytokine release syndrome in CAR-T-treated B-cell acute lymphoblastic leukemia.

Effect of interferon induced transmembrane protein 1 ( IFITM1 ) upregulation to cytokine release syndrome in CAR-T-treated B-cell acute lymphoblastic leukemia.

Journal: Chinese medical journal

Published: December 29, 2024

Indocyanine green-mediated fabrication of urchin-like hydroxyethyl starch nanocarriers for enhanced drug tumor EPR and deep penetration effects.

Indocyanine green-mediated fabrication of urchin-like hydroxyethyl starch nanocarriers for enhanced drug tumor EPR and deep penetration effects.

Journal: International journal of biological macromolecules

Published: January 12, 2024

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques.

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques.

Journal: Frontiers in bioengineering and biotechnology

Published: October 13, 2023

Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.

Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.

Journal: Cancer communications (London, England)

Published: June 07, 2023

Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy.

Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy.

Journal: Clinical and translational medicine

Published: December 01, 2022

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.

Journal: Blood cancer journal

Published: November 23, 2022

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.

Journal: Journal of hematology & oncology

Published: November 13, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026